GlassScriptPhysician profile
Isaiah William Wilson
NPI 1376715664
$40,543.60
in general payments reported to CMS, 2019-2025
24 companies · $599 in 2025
The $599 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,682 · 2020: $8,394 · 2021: $11K · 2022: $1,876 · 2023: $7,922 · 2024: $845 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,650 · Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,650.00 |
| Food and Beverage | $1,716.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28,601.81 | 2019-2022 | |
| Abbvie INC. | $10,318.78 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Emd Serono, INC. | $266.87 | 2022-2023 | Mavenclad |
| Avanir Pharmaceuticals, INC. | $223.69 | 2019-2022 | |
| Lundbeck LLC | $139.74 | 2021-2022 | |
| Argenx US, INC. | $138.45 | 2022-2023 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $135.21 | 2021-2024 | |
| Corium, LLC | $113.07 | 2022-2023 | Adlarity |
| Teva Pharmaceuticals USA, INC. | $79.83 | 2022-2023 | Austedo |
| Lilly USA, LLC | $72.78 | 2023 | Reyvow, Emgality |
| Imperative Care, INC | $55.71 | 2025 | Zoom 88-T Large Distal Platform, Zoom Reperfusion Catheter |
| Amgen INC. | $51.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.17 | 2021 | |
| Csl Behring | $42.91 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $37.99 | 2022-2023 | Briviact |
| Avion Pharmaceuticals | $36.27 | 2022 | |
| Neurocrine Biosciences, INC. | $28.56 | 2022-2023 | Ongentys, Ingrezza |
| Ge Healthcare | $21.49 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.75 | 2024 | Nuedexta |
| Alexion Pharmaceuticals, INC. | $19.24 | 2023 | Ultomiris |
| Kyowa Kirin, INC. | $17.77 | 2023 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $15.84 | 2022 | |
| Pfizer INC. | $12.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaiah Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.